|
|
{{if listFind(vars.channel_names, "MSIF News")}} {{endif}}  {{if listFind(vars.channel_names, "MSIF News")}} {{endif}} {{if listFind(vars.channel_names, "MSIF News")}} 
MSIF News
{{endif}}
|
{{if listFind(vars.channel_names, "People With MS News")}} {{endif}}  {{if listFind(vars.channel_names, "People With MS News")}} {{endif}} {{if listFind(vars.channel_names, "People With MS News")}} 
Profile of the Month
{{endif}}
|
{{if listFind(vars.channel_names, "Research News")}} {{endif}}  {{if listFind(vars.channel_names, "Research News")}} {{endif}} {{if listFind(vars.channel_names, "Research News")}} 
Research News
{{endif}}
|
{{if listFind(vars.channel_names, "MS Society News")}} {{endif}}  {{if listFind(vars.channel_names, "MS Society News")}} {{endif}} {{if listFind(vars.channel_names, "MS Society News")}} 
MS News
{{endif}}
|
|
|
|
Making Connections
|
{{if listFind(vars.channel_names, "MSIF News")}}
|
|
MSIF News
 |
 |
| Summaries of new MSIF activities, events, projects, programmes, resources, publications and more. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
|
|
Profile of the Month
|
|
| Summaries of news, views and achievements from people with MS around the world. |
Profile of the Month : January 2010
Adrijana Nikolić
Country: Montenegro
Connection with MS: Mother has MS
Profession: Executive Director, Montenegro MS Association (Udruženje Multiple Skleroze Crne Gore-Podgorica)
Age: 38
After my personal experience with MS I wanted to help other people in a similar situation so I decided to set up a national MS society in Montenegro.
Deutsch English Espanol Francais Italiano
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
|
|
Research News
|
|
| Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London. |
Early MRI in optic neuritis: the risk for disability
In this prospective study the authors investigated whether, in patients with optic neuritis, early MRI findings (within 3 months from onset) influence future disability. The authors found that the presence of lesions in the spinal cord and the cerebellum-brainstem region predicted disability at 6-year follow-up. The presence of early MRI activity (enhancing lesions and appearance of new T2 lesions) was also predictive of higher disability.
authors: Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson AJ, Miller DH
source: Neurology. 2009 Feb 10;72(6):542-50
read more
Rate of brain atrophy in benign vs early multiple sclerosis
The objective of this study was to compare the rate of brain volume loss between benign MS and RRMS. The authors found a lower rate of volume loss in patients with benign MS than that calculated in patients with RRMS, suggesting that this MRI finding is behind the milder disease course of patients with benign MS.
authors: Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR
source: Arch Neurol. 2009 Feb;66(2):234-7
read more
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
The aim of this study was to explore the potential for natalizumab to increase the proportion of patients with relapsing-remitting MS who are free of disease activity. They used the data from the phase III study where natalizumab was compared with placebo (AFFIRM study). The authors found that the proportion of patients with no disease activity, from the clinical and/or MRI point of view, was significantly higher in the natalizumab group.
authors: Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R
source: Lancet Neurol. 2009 Feb 6
read more
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
The aim of this randomised multicentre clinical trial was to investigate the safety and efficacy at 1 year follow-up of interferon beta 1-a combined with methotrexate, or with intravenous steroids, or with both drugs, in patients with RRMS who still had clinical activity despite the treatment with interferon. The authors found no extra benefit from such combinations compared to interferon alone.
authors: Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Collaborators (107)
source: Neurology. 2009 Feb 10;72(6):535-41
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
|
|
MS News
|
|
| Summaries of MS news from websites around the world. |
|
{{endif}}
|
|
Tell a friend
The email you subscribed with us is {{print email}}
Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.
If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here
Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org
|
|
